- Home
- CXAI vs NCNA Comparison
CXAI vs NCNA Comparison
Compare CXAI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXAI | NCNA |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United Kingdom |
| Employees | 41 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 8.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CXAI | NCNA |
|---|---|---|
| Price | $0.25 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.6M | 34.3K |
| Earning Date | 03-20-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.03 |
| 52 Week High | $1.49 | $10.00 |
Technical Indicators
Market Signals| Indicator | CXAI | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 25.40 |
| Support Level | $0.24 | $0.05 |
| Resistance Level | $0.32 | $2.27 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 55.81 | 0.00 |
Price Performance
Historical ComparisonAbout CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.